ACHV compared with ERAS: revenue, margins and what each company keeps, and the suppliers and customers both name

ACHVAchieve Life Sciences, Inc.

Mkt capRevenueRevenue

ERASErasca, Inc.

Mkt capRevenueRevenue

Compare

ACHVAchieve Life Sciences, Inc.

ERASErasca, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

ACHV, solidERAS, dashed

Supply-chain overlap

Revenue flow

ACHV: latest quarter not drawable. ERAS: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ACHV 4

—Sopharma, ADunlistedsupplier

—University of Bristolunlistedsupplier

—Adare Pharma Solutionsunlistedsupplier

—Kristen Slaouiunlistedsupplier

Shared 0

No shared counterparties.

Only ERAS 5

—Emerge Life Sciences, Pteunlistedsupplier

—Guangzhou Joyo Pharmatechunlistedsupplier

—Medshine Discoveryunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—Novartis Pharmaunlistedsupplier

1 more · ERAS chain ›

ACHVAchieve Life Sciences, Inc.

6.83▼−5.06%· post 6.83

Mkt cap$702.8M

ERASErasca, Inc.

14.33▼−4.34%· post 14.20

ClosedOct 30 '26

Mkt cap$5.0B

Compare

ClosedOct 30 '26

ACHVAchieve Life Sciences, Inc.

ERASErasca, Inc.

6.83▼−5.06%post 6.83

Price

14.33▼−4.34%post 14.20

$702.8M

Mkt cap

$5.0B

ACHV6.83▼−5.06%vsERAS14.33▼−4.34%ClosedOct 30 '26